MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2018 International Congress

    Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials

    R. Pahwa, S. Isaacson, J. Jimenez-Shahed, I. Malaty, A. Deik, R. Gandhy, R. Johnson, R. Patni (Kansas City, KS, USA)

    Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…
  • 2018 International Congress

    Utility of Acute Levodopa Challenge Test In Early Parkinsonism

    M. Acharya, A. Biswas, G. Ganguly, S. Das (Kolkata, India)

    Objective: This prospective cohort study was conducted to evaluate the sensitivity and specificity of different outcomes of acute levodopa challenge test(ALCT) (motor improvement, development of…
  • 2018 International Congress

    Motor and non-motor symptoms of a 7.5-year prospective study of patients with Parkinson’s disease

    A. Yoritaka, Y. Shimo, T. Hatano, N. Hattori (Saitama, Japan)

    Objective: Previously, we retrospectively reported the prevalence and risks of motor and non-motor symptoms of a large number of patients (1453) with Parkinson’s disease (PD)…
  • 2018 International Congress

    Efficacy of ND0612 for nocturnal problems and early morning OFF

    F. Stocchi, W. Poewe, T. Rachmilewitz Minei, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

    Objective: ND012 is a drug-device combination delivering liquid L-dopa/carbidopa (LD/CD) via continuous SC infusion. This secondary analysis evaluated the efficacy of 2 dosing regimens (R1:…
  • 2018 International Congress

    Design of a Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa for Parkinson’s Disease (PD) Patients Experiencing Motor Fluctuations

    P. LeWitt, R. Gendreau, J. Meckler, N. Navon (West Bloomfield, MI, USA)

    Objective: To review the design and unique features of an ongoing phase 3 trial of a gastric-retentive formulation of carbidopa/levodopa (CD/LD), the Accordion Pill™ (AP),…
  • 2018 International Congress

    Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease

    C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, M. Hacker, P. Charles, J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

    Objective: To determine whether relatively prevalent variants in the gene for brain-derived neurotrophic factor (Bdnf) are associated with differential efficacy of levodopa or other dopaminergic…
  • 2018 International Congress

    Using saccades as an early test of levodopa treatment in Parkinson’s Disease

    Z.J. Lu, S. Dillon, P. Zetegren, M. Brzezick, C. Kennard, J. FitzGerald, C. (Oxford, United Kingdom)

    Objective: It is important to know what potential confounding effects the medications used to treat Parkinson’s disease (PD) have on eye movement, in order to…
  • 2018 International Congress

    Efficacy of liquid sinemet on non-motor symptoms in Parkinson’s disease

    M. Danoudis, R. Iansek, C. Boon (Cheltenham, Australia)

    Objective: To investigate the short term effect of liquid sinemet on the non-motor symptoms of people with advanced Parkinson’ disease (PD) who experience complex motor…
  • 2018 International Congress

    Variation in the L-dopa motor response in pathologically confirmed Parkinson’s disease

    V. Pitz, N. Malek, K. Grosset, D. Grosset (Glasgow, United Kingdom)

    Objective: To examine the L-dopa-response (improvement in motor symptoms) in published cases of pathologically confirmed Parkinson’s disease (PD). Background: L-dopa responsiveness supports the diagnosis of…
  • 2018 International Congress

    Levodopa Effect on Dual-Tasking in Freezing of Gait in Parkinson’s Disease

    E. Bayram, J. Longhurst, S. Banks, Z. Mari, B. Bluett (Las Vegas, NV, USA)

    Objective: To assess the effect of levodopa on dual-tasking in situations triggering freezing of gait (FOG) in Parkinson’s disease (PD). Background: The frequency and severity…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • “Striatal Hand Signs” and early diagnosis of Parkinson's Disease: The “Monkey-Wrench Sign”.
  • An atypical and interesting feature of Parkinson´s disease
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley